252 related articles for article (PubMed ID: 14645552)
1. Further evidence that papillomavirus capsids exist in two distinct conformations.
Selinka HC; Giroglou T; Nowak T; Christensen ND; Sapp M
J Virol; 2003 Dec; 77(24):12961-7. PubMed ID: 14645552
[TBL] [Abstract][Full Text] [Related]
2. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
Roth SD; Sapp M; Streeck RE; Selinka HC
Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
[TBL] [Abstract][Full Text] [Related]
3. Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA.
Rommel O; Dillner J; Fligge C; Bergsdorf C; Wang X; Selinka HC; Sapp M
J Med Virol; 2005 Jan; 75(1):114-21. PubMed ID: 15543569
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.
Day PM; Thompson CD; Buck CB; Pang YY; Lowy DR; Schiller JT
J Virol; 2007 Aug; 81(16):8784-92. PubMed ID: 17553881
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
[TBL] [Abstract][Full Text] [Related]
6. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses.
Shafti-Keramat S; Handisurya A; Kriehuber E; Meneguzzi G; Slupetzky K; Kirnbauer R
J Virol; 2003 Dec; 77(24):13125-35. PubMed ID: 14645569
[TBL] [Abstract][Full Text] [Related]
7. Immunological analyses of human papillomavirus capsids.
Giroglou T; Sapp M; Lane C; Fligge C; Christensen ND; Streeck RE; Rose RC
Vaccine; 2001 Feb; 19(13-14):1783-93. PubMed ID: 11166904
[TBL] [Abstract][Full Text] [Related]
8. Generation and neutralization of pseudovirions of human papillomavirus type 33.
Unckell F; Streeck RE; Sapp M
J Virol; 1997 Apr; 71(4):2934-9. PubMed ID: 9060652
[TBL] [Abstract][Full Text] [Related]
9. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
Culp TD; Spatz CM; Reed CA; Christensen ND
Virology; 2007 May; 361(2):435-46. PubMed ID: 17222883
[TBL] [Abstract][Full Text] [Related]
10. Heparin increases the infectivity of Human Papillomavirus type 16 independent of cell surface proteoglycans and induces L1 epitope exposure.
Cerqueira C; Liu Y; Kühling L; Chai W; Hafezi W; van Kuppevelt TH; Kühn JE; Feizi T; Schelhaas M
Cell Microbiol; 2013 Nov; 15(11):1818-36. PubMed ID: 23601855
[TBL] [Abstract][Full Text] [Related]
11. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
[TBL] [Abstract][Full Text] [Related]
12. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus.
Selinka HC; Florin L; Patel HD; Freitag K; Schmidtke M; Makarov VA; Sapp M
J Virol; 2007 Oct; 81(20):10970-80. PubMed ID: 17686860
[TBL] [Abstract][Full Text] [Related]
14. Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.
Wang HK; Wei Q; Moldoveanu Z; Huh WK; Vu HL; Broker TR; Mestecky J; Chow LT
Vaccine; 2016 Jun; 34(27):3171-3177. PubMed ID: 27113165
[TBL] [Abstract][Full Text] [Related]
15. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate.
Patterson NA; Smith JL; Ozbun MA
J Virol; 2005 Jun; 79(11):6838-47. PubMed ID: 15890923
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus capsids preferentially bind and infect tumor cells.
Kines RC; Cerio RJ; Roberts JN; Thompson CD; de Los Pinos E; Lowy DR; Schiller JT
Int J Cancer; 2016 Feb; 138(4):901-11. PubMed ID: 26317490
[TBL] [Abstract][Full Text] [Related]
18. Extracellular Conformational Changes in the Capsid of Human Papillomaviruses Contribute to Asynchronous Uptake into Host Cells.
Becker M; Greune L; Schmidt MA; Schelhaas M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29593032
[TBL] [Abstract][Full Text] [Related]
19. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
Combita AL; Touzé A; Bousarghin L; Christensen ND; Coursaget P
J Virol; 2002 Jul; 76(13):6480-6. PubMed ID: 12050360
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus infection requires cell surface heparan sulfate.
Giroglou T; Florin L; Schäfer F; Streeck RE; Sapp M
J Virol; 2001 Feb; 75(3):1565-70. PubMed ID: 11152531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
